Pfizer Global Research and Development

Delvaux

Description

1. Pfizer Global Research and Development. La Jolla, CA. Ann Arbor &. Kalamazoo,. MI. St. Louis, MO. New York, NY. Sandwich,. ENGLAND. Nagoya,. JAPAN ...

Sujets

• Économie
• Economy

Informations

• Publié par: paul.vallen
• Nombre de lectures: 33
• Langue: English

Extrait

PfizerGlobalResearch and Development

Ann Arbor & Kalamazoo, MI

St. Louis, MO

La Jolla, CA

Cambridge, MA

New London & Groton, CT

New York, NY

Sandwich, ENGLAND

Shanghai China

Milan, Italy Nagoya, JAPAN Singapore Mumbai, Amboise, India France

1

Pfizer Therapeutic Areas

Cardiovascular, Metabolic Diseases & Endocrine Central Nervous System Inflammation Allergy and Respiratory Infectious Diseases Pain

Gastrointestinal & Hepatitis Oncology Urology & Sexual Health Ophthalmology Dermatology

2

The TA Model Across the Continuum

Idea

CANdidate Research

First in Patient (FIP) Approval Launch Development Commercial

Pharmaceutical Strategy Group (PSG)

Therapeutic Area Steering Committee (TASC)

Therapeutic Area Leadership Team (TALT)

3

How We Work & Operate Together

 People Leadership Discipline Excellence Productivity Improvement

Discovery Clin R&D

PDM DevOps Research WRAQA Technology WWPS HR

WWSS Finance

CM Informatics

 People & Community Crossline integration &  experimentation Scientific partnerships Michigan

Groton

La Jolla

Nagoya

Sandwich

St Louis

SRM GO RTC WWM & OR SMG TA  Patient Focus A&R CVMED Dermatology GI/Hep Inflammation ID Project Progression Neuroscience Oncology Ophthalmology Pain SH/Uro Portfolio Goal Delivery

4

Features and advantages of the new TA model Themes Examples Empowered and Nimble Smaller project teams with single Points Project Teams of Accountability for decision making RTARC only governance body for Light Governance Research project teams TA Driven Goals Product goals now split by TA, not site

Priorities of R&D lines aligned with TAs

One PortfolioPhilosophy

Centers of Emphasis to drive science in partnership with all TAs

Creation of Research Portfolio Team for crossTA allocations

R&D Challenges: attrition Low Discovery Yields, high Development Failure Rate 40 Preclinical Development Candidates Scientific ideas

Reasons for Failure: Safety Toxicology / Adverse events / DDI Efficacy Disease / Outcome measures Pharmaceutical

20 Clinical Development Candidates

Prospective Medicines

3 Phase III Candidates 12 Medicines

6